IP Library › Granted Patent US 11,779,662
Granted Patent B2
US 11,779,662 · App. 15/713,324 · Granted Oct 10, 2023

Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide

Inventors: Yana K. Reshetnyak (South Kingstown, RI); Oleg A. Andreev (South Kingstown, RI); Donald M. Engelman (New Haven, CT)
Assignees: University of Rhode Island Board of Trustees; Yale University
A61K49/0056A61B5/0082A61K49/0034A61K49/04A61K49/221A61K49/227C07K14/001C07K19/00C09B69/107C09K11/06G01N33/582A61B5/0071C09K2211/1466
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,662
App. No.
15/713,324
Granted
Oct 10, 2023
Kind
B2
Abstract

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

Claims (21)

1. A pH-triggered polypeptide fluorophore composition comprising the structure:

2. A pH-triggered polypeptide-fluorophore composition comprising the structure:

and wherein the composition further comprises a pharmaceutically acceptable carrier.

3. The composition of claim 2 , wherein the pharrnaceutically acceptable carrier is a buffer.

4. The composition of claim 3 , wherein the buffer comprises phosphate-buffered saline.

5. The composition of claim 1 , wherein the composition is an intravenous, intraperitoneal, or intravessical composition.

6. The composition of claim 5 , wherein the composition is an intravenous composition.

7. The composition of claim 5 , wherein the composition is formulated for intravessical administration.

8. The composition of claim 6 , wherein the composition is formulated for injection.

9. The composition of claim 1 , wherein the composition is a subcutaneous, topical, oral, or mucosal composition.

10. The composition of claim 9 , wherein the composition is a subcutaneous composition.

11. The composition of claim 10 , wherein the composition is formulated for subcutaneous administration.

12. The composition of claim 10 , wherein the composition is formulated for injection.

13. The composition of claim 2 , wherein the composition is an intravenous, intraperitoneal, or intravessical composition.

14. The composition of claim 13 , wherein the composition is an intravenous composition.

15. The composition of claim 13 , wherein the composition is formulated for intravessical administration.

16. The composition of claim 14 , wherein the composition is formulated for injection.

17. The composition of claim 2 , wherein the composition is a subcutaneous, topical, oral, or mucosal composition.

18. The composition of claim 17 , wherein the composition is a subcutaneous composition.

19. The composition of claim 18 , wherein the composition is formulated for subcutaneous administration.

20. The composition of claim 18 , wherein the composition is formulated for injection.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2021
From: RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION
To: UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES
Reel/Frame 056255/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2020
From: ENGELMAN, DONALD M.
To: YALE UNIVERSITY
Reel/Frame 053302/0480 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2020
From: RESHETNYAK, YANA K.; ANDREEV, OLEG A.
To: RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION
Reel/Frame 053302/0589 →
CONFIRMATORY LICENSE Recorded Sep 29, 2017
From: UNIVERSITY OF RHODE ISLAND
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044062/0107 →
Continuity (2)
Provisional Application 62398448 · Sep 22, 2016
Related Publication 20180117183A1 · May 3, 2018
Cited By (2)
US 12,285,462 US 12,290,575